Compare GSK plc (GSK) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs IAC/Interactivecorp — how do they compare? GSK plc trades at $46.62 (market cap $91.88B), while IAC/Interactivecorp trades at $41.28 (market cap $3.05B). The key difference: GSK plc is far larger — about 30.1× IAC/Interactivecorp's market cap, and GSK plc pays a 3.9% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and IAC/Interactivecorp for 79 Days on average.
| GSK | PPLI | |
|---|---|---|
Market Cap | $91.88B | $3.05B |
Volume | 7,730,529 | 931,019 |
Sector | Health | Media |
52-Week High | $61.18 | $47.62 |
52-Week Low | $43.24 | $31.52 |
Typical Hold Time | 93 Days | 79 Days |
Enterprise Value | $111.88B | $3.53B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
PPLI trades at $40.85, up 0.64% on the day, with a bullish technical signal from moving averages. The stock has shown volatile earnings, missing estimates in Q4 2025 and Q1 2026 but beating in Q2 2026. Recent news highlights potential M&A activity, with MGM Resorts considering a bid for the company after PPLI withdrew its own offer to buy MGM, driving significant price movement. Valuation ratios appear attractive with a P/E of 6.92 and P/B of 0.6, though profitability metrics are mixed amid revenue declines from $5.2B in 2022 to $2.4B in 2025.
The outlook is cautiously optimistic due to strong analyst support (71.43% buy ratings) and speculative M&A upside, but risks include inconsistent earnings, high debt levels, and competitive pressures in the media sector. Net cash flow turned deeply negative in 2025 at -$820.42M, underscoring financial volatility. Investors should weigh the low valuation against execution challenges and industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
